PCOS Rename to PMOS: Critics Cite Diagnostic, Therapeutic Concerns

Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age, with a prevalence estimated between 5% and 10% globally, depending on the diagnostic criteria applied. The syndrome is characterized by a constellation of signs and symptoms, including hyperandrogenism (clinical or biochemical), ovulatory dysfunction (oligo- or anovulation), and polycystic ovarian morphology on ultrasound. However, the clinical presentation of PCOS extends beyond these reproductive manifestations, frequently encompassing significant metabolic disturbances such as insulin resistance, dyslipidemia, and an increased risk of type 2 diabetes mellitus and cardiovascular disease. This multifaceted presentation has long prompted discussions regarding the adequacy of the current nomenclature, which some argue overemphasizes the ovarian component while potentially downplaying the systemic metabolic burden.

The term 'Polycystic Ovary Syndrome' was first coined in 1935 by Stein and Leventhal, who described a syndrome of amenorrhea, hirsutism, and enlarged ovaries. Over subsequent decades, understanding of the condition evolved, leading to various diagnostic criteria. The National Institutes of Health (NIH) criteria, established in 1990, required both hyperandrogenism and ovulatory dysfunction. The Rotterdam criteria, introduced in 2003 by the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM), broadened the definition by requiring two out of three criteria: hyperandrogenism, ovulatory dysfunction, or polycystic ovarian morphology. This expansion led to the identification of different PCOS phenotypes, some of which do not present with overt hyperandrogenism or polycystic ovaries, further complicating the naming debate. The Androgen Excess and PCOS Society (AE-PCOS Society) criteria, proposed in 2006, emphasized hyperandrogenism as a mandatory component, reflecting its central role in the pathophysiology.

The current proposal to rename PCOS to Polycystic Ovarian Metabolic Syndrome (PMOS) stems from a desire to more accurately reflect the condition's systemic nature. Proponents of PMOS argue that the 'syndrome' in PCOS is vague and does not adequately convey the significant metabolic health risks associated with the condition. They contend that explicitly including 'Metabolic' in the name would enhance awareness among patients and healthcare providers regarding the long-term implications beyond reproductive health. This could, theoretically, lead to earlier screening for metabolic complications, such as impaired glucose tolerance, dyslipidemia, and hypertension, and a more proactive approach to their management. The argument is that a name change could shift the clinical focus from solely addressing reproductive symptoms (e.g., infertility, hirsutism) to a more holistic management strategy that prioritizes metabolic health, potentially reducing the incidence of type 2 diabetes and cardiovascular events in this patient population.

However, the proposed renaming to PMOS has met with considerable opposition. Critics raise several concerns, primarily focusing on the potential for diagnostic confusion and the misrepresentation of the condition's full spectrum. One major point of contention is that not all individuals diagnosed with PCOS exhibit significant metabolic dysfunction. While insulin resistance is prevalent, its severity varies, and some phenotypes of PCOS are predominantly reproductive, with minimal metabolic derangements. Renaming the condition to PMOS could imply that metabolic dysfunction is a mandatory component for diagnosis, potentially excluding patients who meet current PCOS criteria but do not present with overt metabolic syndrome features. This could lead to a reduction in the diagnosed prevalence of the condition, leaving some patients without an appropriate diagnosis and access to care.

Furthermore, the term 'Polycystic Ovarian' within PMOS still places emphasis on the ovarian morphology, which is itself a point of debate. Polycystic ovarian morphology (PCOM) on ultrasound is present in a significant proportion of healthy women (up to 20-25%) who do not meet other diagnostic criteria for PCOS. Conversely, some women with clear clinical and biochemical signs of PCOS do not exhibit PCOM. The continued inclusion of 'Polycystic Ovarian' in the proposed name may perpetuate the misconception that ovarian cysts are the primary pathological feature, rather than a morphological marker that may or may not be present. This could detract from the understanding of PCOS as a complex endocrine disorder driven by hormonal imbalances, particularly hyperandrogenism, and insulin resistance, rather than a primary ovarian pathology.

Another critical concern is the potential impact on patient identity and advocacy. Many patients with PCOS have formed communities and advocacy groups around the existing name. A change in nomenclature could disrupt these established networks, potentially causing confusion and a sense of disenfranchisement. Patients may feel that their condition is being redefined in a way that does not fully capture their lived experience, particularly if their primary concerns are reproductive or dermatological rather than metabolic. The psychological impact of a name change, and the potential for patients to feel their condition is being minimized or misunderstood, cannot be overlooked.

From a therapeutic perspective, critics argue that the renaming to PMOS might inadvertently narrow the focus of treatment. If the name emphasizes metabolic aspects, there is a risk that clinicians might prioritize metabolic interventions (e.g., metformin, lifestyle modifications for weight management) over treatments for hyperandrogenism (e.g., oral contraceptives, anti-androgens) or ovulatory dysfunction (e.g., clomiphene citrate, letrozole). While metabolic management is undeniably crucial, a comprehensive approach to PCOS requires addressing all facets of the syndrome based on individual patient presentation and priorities. A name that overemphasizes one aspect could lead to an imbalanced treatment strategy, potentially neglecting other significant symptoms that impact a patient's quality of life.

The process of renaming a well-established medical condition is complex and requires broad consensus from international medical societies, patient advocacy groups, and regulatory bodies. Any change must be supported by robust evidence demonstrating that the new name offers clearer diagnostic utility, improves patient outcomes, and enhances understanding without introducing new ambiguities. The current debate highlights the challenges in finding a single name that accurately encapsulates the diverse clinical phenotypes and pathophysiological mechanisms of a complex syndrome like PCOS. While the intent behind PMOS to highlight metabolic risk is valid, the potential for unintended consequences on diagnosis, patient care, and research focus necessitates careful consideration and further deliberation among stakeholders.

The discussion around PCOS nomenclature underscores a broader challenge in medicine: how to name conditions that present with heterogeneous symptoms and involve multiple organ systems. The desire for a name that is both precise and comprehensive often conflicts with the need for simplicity and clinical utility. For PCOS, the ongoing dialogue reflects a growing understanding of its systemic nature, moving beyond a purely gynecological perspective. However, the proposed PMOS name, while addressing some limitations, introduces new ones, particularly regarding diagnostic inclusivity and the potential for an overly narrow focus on metabolic features. The path forward likely involves continued research into the underlying mechanisms of PCOS, which may eventually lead to a more nuanced classification system that better guides diagnosis and personalized treatment strategies, rather than a single, potentially reductive, name change.